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852Iron Overload in Patients with Acute Leukemia or MDS
Undergoing Myeloablative Stem Cell Transplantation
Philippe Armand,1 Haesook T. Kim,2 Joanna Rhodes,3 Marie-Michele Sainvil,1 Corey Cutler,1
Vincent T. Ho,1 John Koreth,1 Edwin P. Alyea,1 Doreen Hearsey,1
Ellis J. Neufeld,4 Mark D. Fleming,5 Hanno Steen,5 Damon Anderson,5
Raymond Y. Kwong,6 Robert J. Soiffer,1 Joseph H. Antin1Patients with hematologic malignancies undergoing allogeneic stem cell transplantation (HSCT) commonly
have an elevated serum ferritin prior to HSCT, which has been associated with increased mortality after
transplantation. This has led to the suggestion that iron overload is common and deleterious in this patient
population. However, the relationship between serum ferritin and parenchymal iron overload in such pa-
tients is unknown.We report a prospective study of 48 patients with acute leukemia (AL) or myelodysplastic
syndromes (MDS) undergoing myeloablative HSCT, using magnetic resonance imaging (MRI) to estimate liver
iron content (LIC) and cardiac iron. The median (and range) pre-HSCT value of serum ferritin was 1549 ng/
mL (20-6989); serum hepcidin, 59 ng/mL (10-468); labile plasma iron, 0 LPI units (0.0-0.9). Eighty-five percent
of patients had hepatic iron overload (HIO), and 42% had significant HIO (LIC$5.0 mg/gdw). Only 1 patient
had cardiac iron overload. There was a strong correlation between pre-HSCT serum ferritin and estimated
LIC (r 5 .75), which was mostly dependent on prior transfusion history. Serum hepcidin was appropriately
elevated in patients with HIO. Labile plasma iron elevation was rare. A regression calibration analysis
supported the hypothesis that elevated pre-HSCT LIC is significantly associated with inferior post-HSCT
survival. These results contribute to our understanding of the prevalence, mechanism, and consequences
of iron overload in HSCT.
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There is growing evidence that iron overload is
common in patients with hematologic malignancies
undergoing hematopoietic allogeneic stem cell trans-
plantation (HSCT), and that it may have a deleterious
effect on the outcomes of transplantation. This evi-
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6/j.bbmt.2010.09.006as a surrogate for iron burden, which have repeatedly
shown that an increased pre-HSCTserum ferritin is as-
sociated with inferior post-HSCT survival [1-11],
especially in patients who receive myeloablative
conditioning. In most of these studies, the predominant
association is between high ferritin and nonrelapse
mortality (NRM) rather than with disease relapse.
Some reports have suggested an increase in acute
graft-versus-host disease (GVHD) [1,7,8] or hepatic
veno-occlusive disease [3,12-14], but the strongest
evidence seems to be for an increase in the risk of
infection [4,6,8,9,15,16]. Unfortunately, serum ferritin
is also an acute phase reactant and is therefore an
imperfect surrogate for iron burden. This could be
particularly problematic in this group of patients,
who are frequently receiving chemotherapy or dealing
with infectious issues pretransplantation. Therefore,
although ferritin clearly has prognostic value, it is not
clear that iron overload is itself an important
contributor to post-HSCT morbidity and mortality.
Moreover, we have little understanding of the mecha-
nisms that may underlie iron overload in this setting
or of the distribution of iron in those patients.
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with myelodysplastic syndromes (MDS) or acute
leukemia undergoing myeloablative HSCT, using he-
patic and cardiac magnetic resonance imaging (MRI)
to better estimate the prevalence of iron overload,
and to clarify the relationship between iron burden
and serum ferritin. We also measured labile plasma
iron (LPI) and hepcidin levels in plasma and urine.MATERIALS AND METHODS
Patients
We approached consecutive adult patients with
acute myelogenous (AML) or lymphoblastic (ALL)
leukemia or MDS who were scheduled to undergo al-
logeneic HSCT with myeloablative conditioning at
the Dana-Farber/Brigham and Women’s Hospital
(DF/BWH) transplant program beginning in June
2008. Patients who agreed to participate were enrolled
in this prospective observational study. Accrual closed
in January 2010. Sixteen eligible patients were not
enrolled, because of patient refusal, logistic challenges
of obtaining the required testing, or claustrophobia
precluding MRI. Patients who met criteria for
a companion study of pretransplantation chelation
(NCT00658411) could enroll in the chelation study
instead, and because we obtained the same pretrans-
plantation studies as in the observational study (prior
to any chelation), they are included in this report. A to-
tal of 48 patients are included in this analysis. Informed
consent was obtained from all patients. Institutional
review board (IRB) approval was obtained from theOf-
fice for the Protection of Research Subjects (OPRS) at
Dana-Farber/Harvard Cancer Center to perform this
study. This study was performed in accordance with
the principles of the Declaration of Helsinki, and
registered at ClinicalTrials.gov (NCT00954720).
Transplantation
Patients were transplanted under several treatment
and investigational protocols over the period covered
by this study. All patients received an ablative condi-
tioning regimen, mostly cyclophosphamide plus total
body irradiation (88% of patients). Ninety percent of
patients received a peripheral blood stem cell graft;
44% of patients had a matched related donor, 48%
a matched unrelated donor, and 8% received a mis-
matched transplant. GVHD prophylaxis regimens
consisted mostly of a combination of calcineurin in-
hibitor and methotrexate, with or without sirolimus
[17].
Laboratory Studies
Serum iron, total iron binding capacity, ferritin,
and C-reactive protein were measured using standardcommercial assays in the clinical laboratory at Brigham
and Women’s Hospital. We defined adjusted serum
ferritin (ASF) as serum ferritin (in ng/mL) divided by
the log10 of C-reactive protein (CRP) (in mg/L),
when CRP is higher than 10.0 mg/L. If CRP is
\10.0 mg/L, the ASF is simply the serum ferritin
(see Results section on ASF). HFE genotyping was
performed using a commercial assay (Mayo Clinic,
Rochester, MN). Patients’ plasma and urine were pro-
spectively collected and frozen for measurements of
hepcidin. LPI was measured in plasma by Afferix Ltd
(Ashkelon, Israel). Transfusion history was obtained
from the medical records of DF/BWH blood bank
and of all the institutions where the patients reported
to have received transfusions.Hepcidin Assay
The assay was based on the detection and quantifi-
cation of endogenous hepcidin relative to that of a sta-
ble isotope-labeled hepcidin internal standard added
to samples at a known concentration [18]. The plasma
version of this method has been recently validated
(Anderson et al., manuscript in preparation). Plasma
or urine samples stored at 80C were thawed at 25C
and vortexed briefly. Internal standard was mixed
with neat plasma or urine, and samples were equili-
brated at 25C in 96-well polypropylene microtiter
filter plate wells. Binding buffer was mixed, and sam-
ples were then subjected to centrifugation 10 min at
3000  g at 25C in an Eppendorf microcentrifuge.
In situ hepcidin enrichment was performed by incu-
bating plasma filtrate (5 mL) on the MALDI spot sur-
face for 20 minutes under controlled environmental
conditions (20C, 50% relative humidity). Following
incubation, plasma/urine was removed and several
brief (10-second) washes (5 mL) were performed using
finishing solution prior to MALDI-TOF MS analysis,
performed as previously described [18].Magnetic Resonance Imaging (MRI)
All patients had an MRI scan for liver and cardiac
iron assessment prior to transplantation. All scans
were done at Brigham and Women’s Hospital and
read under the supervision of 1 of the study investiga-
tors (R.Y.K.). All MRI studies were performed on
a 1.5-Tesla magnetic resonance system (General Elec-
tric HealthCare, Excite HDx, Piscataway, NJ) with an
8-channel phased-array receiving surface coil. MRI in-
cluded both cardiac and liver imaging with dedicated
pulse sequences. Vector ECG signals were used for
cardiac gating for all cardiac MRI data acquisition
and for patient monitoring. Cardiac imaging included
cine imaging of ventricular structure and function and
imaging for quantification of myocardial iron content.
Cine imaging was performed using standard cine
854 Biol Blood Marrow Transplant 17:852-860, 2011P. Armand et al.steady-state free precession fast gradient-echo tech-
nique with the following parameters (repetition time
3 milliseconds, echo time 1-1.3 milliseconds, flip angle
45-55 degrees, in-plane spatial resolution 1.5  2 mm
at a slice thickness of 8 mm and 0 mm interslice spac-
ing). Quantification of myocardial iron was performed
using a validated fast gradient-echo technique that ac-
quires 8 images from a range of echo times (ranging
from 2 milliseconds to 30 milliseconds, echo spacing
4 milliseconds) in a midventricular short-axis location
[19]. Hepatic iron was quantified using the same pulse
sequence technique but without cardiac gating and
acquired in a transaxial location of the liver. For liver
iron imaging, this pulse sequence technique typically
acquires 16 images corresponding to a range of pro-
gressive echo times from 1 millisecond to 32 millisec-
onds (echo spacing of 2 milliseconds). No intravenous
contrast was used during MRI studies. Breath holds
were performed during cardiac imaging to minimize
respiratory motions. Offline analysis was performed
to obtain left ventricular volumes and ejection fraction
using commercial available software (QMASS 7.1,
Medis, Leiden, The Netherlands) or iron quantifica-
tion using validated research software (CineTool
version 8.0, General Electric Healthcare). Liver iron
content was estimated from the hepatic parenchyma
T2* value using the following formula [20]: LIC
(mg/g dry weight) 5 25.4/T2* (in milliseconds) 1
0.202.Statistics
Patient baseline characteristics were analyzed de-
scriptively. Correlations between various parameters
were assessed graphically using a hierarchical cluster-
ing tree and estimated using the Spearman correlation
coefficient and Hoeffding’s D statistics. To establish
a cutoff value for predictive serum ferritin, adjusted
serum ferritin, and transfusion history, analysis of the
receiver operating characteristic (ROC) curves was
performed. Regression calibration was performed us-
ing the method of Rosner and colleagues [21,22].
This method corrects bias in estimates of relative risk
of covariates obtained from regression models
because of measurement error. We reanalyzed from
our previous study [3] the survival of 321 patients
with AML, ALL, or MDS who underwent myeloabla-
tive HSCT, assuming that ferritin was measuring LIC
with measurement error. We used the present dataset
as the source of external validation for the relationship
between LIC and serum ferritin. We corrected the es-
timates of the hazard ratio for mortality of elevated fer-
ritin in the proportional hazards model using the
BLINPLUS8 macro for SAS (provided by Dr. Ros-
ner). All calculations were done using SAS 9.2 (SAS
Institute Inc., Cary, NC).RESULTS
Patient Characteristics
This analysis includes 48 patients who underwent
myeloablative HSCT for AML, ALL, or MDS. Their
demographic and clinical characteristics are summa-
rized in Table 1. The median age was 47 years (range:
18-63). Sixty percent of patients had AML, 23% had
ALL, and 17% had MDS. Most were transplanted
with early stage disease, after having received a median
of 2 (range: 0-6) prior lines of therapy. Patients had
received a median of 20 packed red blood cells units
(PRBCs) prior to their pre-HSCT MRI (range: 0-
77). Table 2 details the iron-related data for this
patient cohort. The median serum ferritin was 1549
ng/mL (range: 20-6989; upper limit of normal
(ULN), 300 ng/mL, which changed during the course
of this study at our institution to 400 ng/mL). The
distribution of serum ferritin values is shown in
Figure 1A. Median transferrin saturation was 35%
(range: 5%-91%). H63D or C282Y mutations were
assayed in all patients; 31% were heterozygous for 1
mutation, but none had a homozygous or a compound
heterozygous mutation. LIC was estimated using MRI
T2* measurement. Median LIC was 3.1 mg/g dry
weight (mg/gdw) (range: 0.6-12.9; ULN, 1.8 mg/
gdw); 85% had hepatic iron overload (HIO), defined
as LIC above the upper limit of normal. We defined
significant HIO as LIC $5.0 mg/gdw (see Discus-
sion). Based on this definition, 42% of patients had sig-
nificant HIO. The distribution of LIC values is shown
in Figure 1B. Only 1 patient had evidence of cardiac
iron overload (defined as cardiac T2* \20 millisec-
onds); this patient was heterozygous for the C282Y
mutation, had AML, a serum ferritin of 5523 ng/mL,
a serum hepcidin of 139 ng/mL, an LPI of 0.0 units,
and an estimated LIC of 5.6 mg/gdw. This patient
was also the only one who exhibited significant left
ventricular dysfunction (left ventricular ejection frac-
tion [LVEF] 34%); none of the other patients had an
LVEF below 40%.Correlations
We investigated correlations between LIC and
other potentially relevant baseline characteristics
(Table 3). The strongest correlations were between
LIC, serum ferritin and transfusion history. The
Spearman correlation coefficient between LIC and se-
rum ferritin was 0.75, and between LIC and number of
prior red cell transfusions was 0.81. Ferritin itself was
strongly correlated to transfusion history (r5 .85). Of
note, LIC had only a weak association with transferrin
saturation (r5 .36) and cardiac T2* (r52.33) (cardiac
T2* is inversely related to cardiac iron content; be-
cause we used a nonparametric correlation coefficient,
it would not improve by using the inverse or log of
Table 1. Baseline Characteristics of the Patients
Variable No. (%)*
Number of patients 48
Age (years)
Median (range) 47 (18-63)
Disease
MDS 8 (17)
Low risk† 3 (6)
High risk† 5 (10)
AML 29 (60)
ALL 11 (23)
Stage at HSCT
Early 41 (85)
Untreated 8 (17)
CR1 25 (52)
CR>1 8 (17)
Advanced 7 (15)
Induction failure/PR 2 (4)
Relapse 5 (10)
Number of prior treatments
Median (range) 2 (0-6)
Cytogenetics
Favorable 3 (6)
Intermediate 20 (42)
Adverse 25 (52)
MDS indicates myelodysplastic syndromes; AML, acute myelogenous
leukemia; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic
stem cell transplantation; CR, complete remission; PR, partial remission.
*Percentages may not add to 100 because of rounding.
†Low-risk MDS includes refractory anemia with or without ringed side-
roblasts, and refractory cytopenias with multilineage dysplasia with or
without ringed sideroblasts; high-risk MDS includes refractory anemia
with excess blasts.
Table 2. Iron-Related Parameters
Variable No. (%)*
Number of patients 48
Serum values
Ferritin (ng/mL) (median, range) 1549 (20-6989)
Patients with ferritin > ULN† 42 (88%)
Patients with ferritin >1000 ng/mL 33 (69%)
Patients with ferritin >2500 ng/mL 11 (23%)
C-reactive protein (median, range)‡ 4.3 (0.4-209)
C-reactive protein > ULN§ 16 (33%)
Adjusted ferritin‡¶ (median, range) 1297 (20-6989)
Transferrin saturationt (median,
range)
35% (5%-91%)
Labile plasma iron (median, range)
(in LPI units)**
0 (0.0-0.9)
Low-positive labile plasma iron†† 0 (0%)
Positive labile plasma iron†† 3 (7%)
Serum hepcidin‡‡ (median, range)
(ng/mL)
59 (10-468)
Serum hepcidin > ULN§§ 29 (74%)
Urine hepcidin¶¶ (median, range)
(ng/mg creatinine)
110 (5-955)
MRI results
Estimated LIC (mg/g dry weight)tt
(median, range)
3.1 (0.6-12.9)
Patients with liver iron overload
(LIC > ULN***)
41 (85%)
Patients with significant liver iron
overload (LIC $5 mg/g dry weight)
20 (42%)
Patients with LIC $7 mg/g dry
weight
9 (19%)
Cardiac T2* (msec) (median, range) 57 (13-171)
Patients with cardiac iron overload
(T2* < LLN†††)
1 (2%)
HFE genotype‡‡‡
Wild type 33 (69%)
H63D heterozygous 10 (21%)
C282Y heterozygous 5 (10%)
Transfusion history
Prior PRBCs (median, range) 20 (0-77)
ULN indicates upper limit of normal; LIC, liver iron content; LLN, lower
limit of normal; PRBCs, packed red blood cell units.
*Percentages may not add to 100 because of rounding.
†ULN for serum ferritin 5 400 ng/mL.
‡C-reactive protein not available for 1 patient.
§ULN for C-reactive protein 5 8.0 mg/L.
¶Ferritin adjusted by dividing by log(CRP) when CRP>10. See text for
explanation.
tData missing on 2 patients.
**Available on 45 patients.
††Low-positive LPI is between 0.4 and 0.6 units; positive is $0.6 units.
‡‡Measurements were unavailable for 6 patients, and not technically
obtainable for 3 patients.
§§Divided by simultaneously measured urine creatinine. Measurements
were unavailable for 13 patients, and not technically obtainable for 2
patients.
¶¶Upper limit of normal in this assay 30 ng/mL.
ttBased on hepatic T2*.
***ULN for liver LIC 5 1.8 mg/g dry weight.
†††LLN for cardiac T2* 5 20 msec.
‡‡‡No patients were homozygous or compound homozygous.
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ber of prior therapies (r 5 .55), presumably because
this variable was itself correlated to transfusion history
(r 5 .76). LIC was also significantly associated with
disease stage, presumably because disease stage was it-
self associated with transfusion history (median num-
ber of red cell units transfused was 19 for patients
with early stage disease versus 34 for those with ad-
vanced stage disease, P 5 .025). Finally, there was no
significant association between LIC and HFE geno-
type. When transfusion history (or ferritin), number
of prior chemotherapies, and transferrin saturation
were entered in a multivariable regression model for
LIC, only transfusion history (or ferritin) was signifi-
cant (P\ .0001). The model fit was better using trans-
fusion history (R2 5 .62 versus 0.49 using ferritin),
presumably because ferritin is also influenced by acute
phase issues. Figure 2 depicts the relationship between
LIC and serum ferritin (Figure 2A), and between LIC
and transfusion history (Figure 2C).
Labile Plasma Iron (LPI)
We measured pre-SCT LPI in 45 of the 48 pa-
tients, at the same time as other iron parameters.
Thirty-eight out of 45 patients (84%) had no detect-
able LPI pre-SCT; the remaining had pre-SCT LPI
between 0.1 and 0.9 LPI units, among whom 4 (9%)
had low-positive LPI (0.4-0.6 units), and 3 patients(7%) had positive LPI ($0.6 units). There was no
meaningful correlation between LPI and LIC, serum
ferritin, transferrin saturation, or transfusion history.
Also, the patients with positive LPI were not those
with the highest ferritin, LIC, or transferrin satura-
tion. For example, none of the patients with transferrin
saturation .75% had positive or low-positive LPI.
Figure 1. Distribution of pretransplantation serum ferritin and liver
iron content (estimated by MRI). (A) Serum ferritin (in ng/mL); (B) Liver
iron content (in mg/g dry weight).
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We measured serum hepcidin on 39 of the 48
patients (results were technically not obtainable for 3
and specimens were missing for 6 patients). Median se-
rum value was 59 ng/mL (range: 10-468; ULN in this
assay 30 ng/mL). Serum hepcidin values were strongly
correlated to serum ferritin (r5 .70) and to transfusion
burden (r 5 .65). They correlated to a lesser extent to
LIC (r 5 .53), and weakly to C-reactive protein (r 5
.39). Similar but weaker correlations were obtained
using serum hepcidin divided by log10(transferrin sat-
uration), which has been proposed as a better measure
of the appropriateness of the hepcidin response to iron
loading (eg, r5 .44 with LIC and r5 .63 with ferritin).
In a linear regression model using both LIC and CRP
as covariates (which had no correlation with each
other), both showed a significant association (P 5
.009 and P\ .0001, respectively). We also measured
urine hepcidin (divided by urine creatinine to adjust
for urine concentration). Samples were available for
35 patients, of which 2 were technically not obtainable,
leaving 33 usable samples. Median adjusted urine
hepcidin was 110 ng/mg creatinine (range: 5-955).
Urine hepcidin was moderately correlated to serum
ferritin (r5 .52), and poorly to LIC (r5 .31). The cor-
relation between serum and urine hepcidin was modest
(r 5 .41).
Adjusted Serum Ferritin
Because ferritin is an acute phase reactant, we
attempted to derive an ASF that would take this into
account. We used CRP, another acute phase reactant,
to adjust for inflammatory status (see Materials and
Methods). An ASF was calculable for 47 of the 48
patients. For those patients, the ASFwas slightly better
correlated to LIC than the unadjusted ferritin (Spear-
man r5 .76 versus .73). The relationship between LIC
and ASF is shown in Figure 2B.
Predicting Elevated LIC
Given the costs and discomfort (mostly claustro-
phobia) associatedwithMRI scanning, it would be use-
ful to be able to predict which patients are likely to have
significant hepatic iron overload (HIO) using readily
available measurements. Based on the above, the best
such candidates would be serum ferritin or transfusion
history. We performed an analysis of ROC curves for
each of those tests, using as outcome significant HIO
(LIC $5.0 mg/gdw). Both measurements produced
similar results (see Table 4 for selected cutoff points).
Combining ferritin with transfusion history did not
improve the test characteristics.
LIC and Posttransplantation Survival
We and others have previously reported a strong
association between pre-HSCT hyperferritinemia anddecreased overall survival (OS) [1-11]. Although those
data argue that iron overload is detrimental in the
context of transplantation, the major question is
whether ferritin is an adequate surrogate for iron
overload, or whether other causes of hyperferritinemia
(such as acute phase reaction) may, in fact, explain
the association with posttransplantation mortality.
The strong correlation between serum ferritin and
LIC described in the present study argues that most
of the variability in ferritin is explained by variability
in LIC. Because our cohort is not of sufficient power
to check for a significant effect of HIO on OS, we
sought to use the present data on the relationship
between LIC and ferritin to reexamine our prior data
on ferritin and post-HSCT outcome [3]. Specifically,
we considered, within the cohort of patients who un-
derwent myeloablative HSCT between 1997 and
2005 at our institution, and who were described in
our previously published study [3], the 321 patients
with MDS, AML, or ALL (who should most closely
resemble the cohort in the present study, other than
the time period of HSCT). Using the method
proposed by Rosner et al. [21,22], we performed
regression calibration on the multivariable proportional
hazards model to account for the error associated
with the measurement of LIC, using the present
dataset as our external validation study. The
uncorrected hazard ratio (HR) for mortality
Table 3. Association between Liver Iron Content (Estimated
by MRI) and Other Baseline Characteristics
Variable Value*†
Correlations*
Number of red cell units transfused 0.81
Serum ferritin 0.75
Adjusted serum ferritin‡ 0.76
Number of prior therapies 0.55
Serum hepcidin concentration 0.53
Transferrin saturation 0.36
LVEF 20.34
Cardiac T2* 20.33
Urine hepcidin concentration 0.31
Labile plasma iron 0.18
Age 20.04
Associations†
Stage of disease (early versus
advanced)§
3.0 vs. 6.6 (p50.048)
HFE genotype
C282Y heterozygosity versus
wild type
5.2 vs. 3.0 (p50.7)
H63D heterozygosity versus
wild type
2.9 vs. 3.0 (p51.0)
LVEF, left ventricular ejection fraction.
*Correlation was examined using the Spearman correlation coefficient.
†Association tested using Wilcoxon rank-sum test, reported as differ-
ence in median LIC and associated P value.
‡Ferritin adjusted by dividing by log(CRP) when CRP >10. See text for
explanation.
§Early stage disease includes patients with AML in complete remission
or untreated MDS, whereas advanced stage includes all other patients
(see Table 1).
Biol Blood Marrow Transplant 17:852-860, 2011 857Iron Overload in Stem Cell Transplantationassociated with LIC (as a continuous variable) was 1.2
(P 5 .00001); the corrected HR was 1.2 (P 5 .005).
Thus, assuming that ferritin measures LIC with
error, and using the present study to correct for that
error, this analysis suggests that increasing pre-
HSCT LIC is associated with worse OS after ablative
HSCT.Figure 2. Relationship between liver iron content, ferritin, and trans-
fusion history. (A) Scatterplot of liver iron content (in mg/g dry weight)
versus serum ferritin (in ng/mL); (B) Liver iron content versus adjusted
serum ferritin (see text for details); (C) Liver iron content versus num-
ber of prior red cell units transfused. Dotted lines were fit to data using
a cubic spline.DISCUSSION
In this study, we sought to better define the
prevalence of iron overload in patients with AML,
ALL, or MDS undergoing myeloablative HSCT, to
better understand the distribution of the various forms
of iron in those patients and the correlations between
their measurements, to begin to investigate what
mechanisms may perturb normal iron homeostasis in
this population, and to leverage those results to
increase our understanding of the impact of iron
overload on post-HSCT survival. We used as our
‘‘gold standard’’ measurement of iron overload the
LIC estimated from MRI T2* reading. Although this
is an indirect measurement, there is a strong correla-
tion between liver T2* values and LIC measured by
liver biopsy [20,23]. It would clearly be impossible to
subject patients with hematologic malignancies to
the risk of liver biopsy for an observational study;
furthermore, even liver biopsy is likely not an
appropriate gold standard, given the significant
intrapatient variability [24].Some limitations of this work must be noted. First,
we cannot rule out a selection bias in this cohort. Sec-
ond, the derivation of an adjusted serum ferritin is in-
tended as an exploratory analysis that should be
validated in other cohorts. Third, we stress that the
use of regression calibration is also only intended as
an exploratory analysis. It is unlikely that a prospective
study of iron overload that is adequately powered for
an analysis of survival could be conducted using
MRI, given the financial and logistic challenges
Table 4. Test Characteristics of Selected Values of Serum Ferritin and Transfusion History to Predict Significant Hepatic Iron
Overload (LIC >5.0 mg/gdw)
Test Sensitivity Specificity PPV NPV
Serum ferritin >1000 ng/mL 90% 46% 55% 87%
Serum ferritin >1500 ng/mL 80% 68% 64% 83%
Serum ferritin >2000 ng/mL 65% 86% 76% 77%
Serum ferritin >2500 ng/mL 50% 96% 91% 73%
More than 15 red blood cell units transfused 100% 50% 59% 100%
More than 20 red blood cell units transfused 75% 71% 65% 80%
More than 25 red blood cell units transfused 55% 86% 73% 73%
More than 30 red blood cell units transfused 50% 96% 91% 73%
PPV indicates positive predictive value; NPV, negative predictive value.
858 Biol Blood Marrow Transplant 17:852-860, 2011P. Armand et al.associated withMRI scanning.We therefore chose the
regression calibration method as the best way to lever-
age the present data in interpreting the many studies
showing an adverse impact of hyperferritinemia. We
present the results of this analysis to support, and not
to prove, the hypothesis that iron overload has
a detrimental effect on post-HSCT survival.
The results presented here offer several insights
into the issue of iron overload in HSCT. First, they
clearly demonstrate that HIO is very common in acute
leukemia/MDS patients undergoing HSCT, with
a prevalence of 85%. It is also clear that iron overload
in this population is at least in large part because of red
cell transfusion, as the number of transfused units is
the single best predictor of elevated LIC in multivari-
able analysis. It is also apparent that patients without
any identified HFE mutations and without aberrantly
low hepcidin levels may have HIO with relatively few
(\20) RBC transfusions. Disease type and stage, prior
chemotherapy, and HFE genotype did not seem to
play a significant role in iron overload in this patient
population, except for the association of prior therapy
with transfusion burden. It is also apparent that signif-
icant HIO is found in a large proportion of those pa-
tients (42% in our cohort). In this respect, it must be
acknowledged that we do not yet know what consti-
tutes clinically meaningful iron overload in this patient
population. In patients with benign hematologic dis-
eases, a threshold of 7 mg/gdw LIC has been used to
predict clinical complications [25]. However, patients
with acute leukemia or MDS undergoing ablative
HSCT are at much higher risk of morbidity and mor-
tality (especially from organ failure or infection) than
patients who are chronically transfused for benign dis-
ease, and the relevant threshold may be lower. Prior
studies using serum ferritin as a surrogate marker for
iron overload have suggested that the ferritin threshold
that best predicts increased post-HSCT mortality is
somewhere between 1000 and 2500 ng/mL. In our
own data [3], the optimal threshold was 2500 ng/mL,
which, based on the relationship between LIC and fer-
ritin (Figure 2A), corresponds roughly to an LIC of 5
mg/gdw. Thus, we used this value as our putative clin-
ically relevant LIC cutoff. If the relevant ferritin cutoff
is closer to 1000 ng/mL, then the relevant LIC cutoffwould be lower than 5 mg/gdw, which would imply an
even higher prevalence of significant HIO.
Our results further suggest that, although signifi-
cant HIO is common, cardiac iron overload is very
rare (2%), which is in contrast to the situation for pa-
tients with thalassemia whose principal iron-related
toxicity may be cardiac. This is not entirely unexpected
because the kinetics of cardiac iron loading are known
to be slower than those of hepatic loading [26].
Patients with AML/ALL/MDS who come to trans-
plantation probably accumulate iron over a much
shorter time frame than patients who are chronically
transfused for benign hematologic diseases. Moreover,
the transfusion threshold to develop cardiac iron
overload may be higher than that for HIO, and
patients with thalassemia often receive many more
transfusions than did the patients in our cohort. At
any rate, on the basis of our results, we would not rec-
ommend cardiac MRI to screen for iron overload in
patients before HSCT, unless they have unexplained
cardiac dysfunction.
Another surprising result of our study is the rarity
of elevated labile plasma iron, and the lack of a relation-
ship between LPI and LIC, even for patients whose
transferrin is highly saturated. On the basis of this, it
would seem imprudent to use ferritin or MRI as surro-
gate markers for LPI, and large prospective studies
measuring LPI will need to be done to determine
whether this parameter influences HSCT outcomes.
It may also be that the previously described increase
in LPI after transplantation (in particular, from the
conditioning regimen) [27] is more important than
pre-HSCT LPI in mediating iron-dependent toxicity
in this setting.
In this cohort, serum hepcidin was strongly corre-
lated with serum ferritin as well as with transfusion
burden, as has been previously described in healthy
volunteers [28]. The good correlation between hepci-
din and ferritin suggests that this component of the
iron homeostasis system in these patients is relatively
well preserved at least prior to HSCT; this argues
against the hypothesis that such patients have hepcidin
levels that are abnormally low for their degree of iron
overload, which would increase their iron loading out
of proportion to transfusion burden. It is interesting to
Biol Blood Marrow Transplant 17:852-860, 2011 859Iron Overload in Stem Cell Transplantationnote that serum hepcidin seemed to be determined
both by iron burden (as reflected by LIC) and inflam-
matory state (as reflected by CRP), consistent with our
understanding of hepcidin biology [29].We also found
that serum hepcidin and urine hepcidin were only
weakly correlated, even after adjusting for urine con-
centration; given our result that serum hepcidin is
more strongly correlated to other iron parameters
(especially LIC) than urine hepcidin, it may be that
serum hepcidin is the preferred measurement.
An important finding from this study is the demon-
stration of a strong correlation between serum ferritin
and LIC. Although this may have been an expected re-
sult, and one that has been previously reported in other
patient populations [30], it has not previously been
demonstrated in patients undergoing HSCT for he-
matologic malignancies. As those patients are often
battling illness or treatment complications around
the time of HSCT, the value of ferritin as a marker
for iron overload has often been questioned. The im-
portance of our result is that it lends some measure
of retrospective validity to the numerous studies that
have used an elevated pre-HSCT serum ferritin as
a surrogatemarker for iron overload and demonstrated
a significant impact on post-HSCT treatment-related
and overall mortality [2-11,31]. This is further
strengthened by our regression calibration analysis.
We are also able to propose some thresholds for
using serum ferritin as a screening test for significant
iron overload. Given that ferritin and transfusion
history are imperfect predictors of iron overload, it is
probably not appropriate to use these parameters
alone to select patients for trials of chelation therapy
or other iron manipulations in HSCT. However, the
thresholds provided here may be useful to select
patients for liver MRI. In particular, it is unlikely
that a patient with a serum ferritin below 1000 ng/
mL, or a patient who has received 15 or fewer red
cell units, would have significant hepatic iron overload.
In conclusion, we have shown that hepatic iron
overload and significant HIO, unlike cardiac iron
overload or elevated LPI, are common in patients
with acute leukemia or MDS undergoing ablative
HSCT, primarily resulting from red cell transfusion
burden. Moreover, serum ferritin may be used as a rea-
sonable surrogate marker of LIC, and in particular, to
select patients for further testing. We anticipate that
longer follow-up on the present patient cohort, as
well as several ongoing and planned prospective stud-
ies, will further elucidate the mechanisms of this phe-
nomenon, the clinical significance of iron overload in
this population, and the best methods to remedy it.ACKNOWLEDGMENTS
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